Study Of Ras(On) Inhibitors In Patients With Gastrointestinal Solid Tumors
Posted Date: Aug 6, 2024
- Investigator: Davendra Sohal
- Type of Study: Drug
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The first three subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel
Criteria:
Inclusion Criteria: All Patients (Unless Otherwise Noted): = 18 Years Of Age Ecog Ps Is 0 To 1 Adequate Organ Function As Outlined By The Study Must Have Pathologically Documented, Pancreatic Carcinoma With Documented Metastatic Disease Or Ras-Mutated, Histologically Or Cytologically Confirmed Colorectal Adenocarcinoma With Documented Unresectable Or Metastatic Disease (Subprotocol A And B) Must Have Pathologically Documented, Poorly Differentiated Pancreatic Carcinoma With Documented Metastatic Disease (Subprotocol C) - Exclusion Criteria: All Patients: Primary Central Nervous System (Cns) Tumors Impaired Gastrointestinal (Gi) Function That May Significantly Alter The Absorption Of Rmc Drugs Major Surgery Within 28 Days Of First Dose Other Inclusion/Exclusion Criteria May Apply.
Keywords:
Crc, Pdac, Ras Mutation
For More Information:
Andrea Ordonez
NULL
cancer@uchealth.com